Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).

AIM: The study was conducted to evaluate efficacy and tolerability of fixed dose combination (FDC) of Losartan and Ramipril in the management of mild to moderate hypertensive Native Asian Indian patients with associated diabetes mellitus. The secondary objective was to evaluate the efficacy of the combination in reducing microalbuminuria. MATERIAL AND METHODS: The study was an open, non-comparative, multicentric clinical trial conducted in seven Indian centres in 315 eligible patients. All the patients were treated with Losartan 50 mg + Ramipril 2.5 mg or Losartan 50 mg + Ramipril 5 mg once a day in 12 weeks and consisted of a total of eight visits. RESULTS: The mean age of patients was 52.93 years (range 45 - 60 years). Of the total patients, 62.86% were males and 37.14% were females. The mean prestudy systolic blood pressure was 160.56 +/- 14.44 which was significantly reduced to 126.85 +/- 9.78 at the end of 12 weeks (P < 0.001). Similarly the mean diastolic blood pressure was 98.91 +/- 8.33 at baseline (stage I) which was significantly reduced to 79.82 +/- 5.42 at the end of 12 weeks (P < 0.001). A mean fall of 33.72 mmHg in systolic blood pressure and the mean fall of 19.10 mmHg was observed in systolic and diastolic blood pressure respectively at the end of the treatment which was statistically highly significant (P < 0.001). The JNC-VII goal of blood pressure < 130/80 was achieved in 79.05% patients after the treatment which losartan and ramipril combination only. Microalbuminuria (urinary albumin excretion > 30 but < 300 mg/day) was seen in 83/250 (33.2%) patients and 135 (54%) patients had clinical proteinuria (albuminuria) at baseline. At the end of the therapy 20.8% patients achieved normoalbuminuria. Good to excellent efficacy response was reported in 98.09% patients and 98.41% patients reported good to excellent tolerability to the treatment. CONCLUSION: The fixed dose combination of Losartan and Ramipril showed good to excellent efficacy response in 98.10% patients and achieved a target blood pressure of 130/80 mmHg in 79.05% patients in 12 weeks. The combination reduced the urinary albumin excretion in majority of the patients with microalbuminuria and proteinuria (the major marker of nephropathy).

Reduction in the dosage schedule of BPL-inactivated neural tissue vaccine for rabies prophylaxis in man.

There exist two different immunization schedules for neural tissue rabies vaccine (NTV) for human use in India, the amount of vaccine given by the schedule recommended by Central Research Institute (CRI), Kasauli, being higher than that recommended by Pasteur Institute of India (PII), Coonoor. A study was therefore undertaken to assess the feasibility of reducing the CRI dosage schedule for rabies prophylaxis. The antirabies antibody response in laboratory animals and human subjects following 7, 10 and 14 daily doses of NTV with or without administering rabies immune globulin (RIG) was much higher than the minimum protective level of 0.5 IU/ml of serum. Based on these results, the CRI schedule could be reduced from 14 x 5 ml of NTV to 10 x 5 ml in class II and class III rabies exposure cases.

Oral infectivity of street and fixed rabies virus strains in laboratory animals.

Oral transmission of rabies could be produced in laboratory animals like mice, guinea pigs and hamsters using challenge virus strain (CVS) and 2 strains of street virus. Study of virus pathway following ingestion suggested predominant neural spread to brain and centrifugal spread to non neural organs like heart and kidneys. However it was found that virus dose required for oral infection was relatively very high. The role of such a transmission in nature needs to be further evaluated, keeping in view the high dose of virus required for oral infectivity and the frequency of consumption of brain by carnivorous animals.

Evaluation of the new rapid rabies immunodiagnosis technique.

The rapid rabies enzyme immuno-diagnosis (RREID) kit was evaluated for its sensitivity and specificity in comparison to fluorescent antibody technique (FAT) and biological test (BT) for the diagnosis of rabies. While 93 per cent correlation was observed in case of fresh brain samples, 71 per cent correlation was noted with glycerol preserved samples, where RREID was more sensitive than FAT. RREID test can be employed for rapid diagnosis of rabies, when facilities for FAT are not available. However, to test, at one time, small number of specimens, the RREID kit needs to be modified.